Outlook Therapeutics, Inc.
OTLKDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 2 past
How OTLK's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ranibizumab | Phase 3 | Age-related Macular Degeneration | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Outlook Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Outlook Therapeutics, Inc.'s (OTLK) pipeline across Phase 3. Its lead program is ranibizumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Outlook Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Outlook Therapeutics, Inc. (OTLK) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track OTLK biotech catalysts?→
Add OTLK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Outlook Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.